What's Going On With Zhongchao Stock Today?

Written by Emily J. Thompson, Senior Investment Analyst

Source: Benzinga

Updated: Sep 30 2024

0mins

ZCMD-6.34%

Should l Buy ZCMD?

Source: Benzinga

Zhongchao Inc. Stock Surge: Zhongchao Inc. (ZCMD) shares are experiencing a significant increase, up 56.1% to $2.10, as investors react positively to new stimulus measures from China, which include lower interest rates and relaxed mortgage regulations.
Market Activity and Trading Options: Over 30 million shares of Zhongchao have been traded, highlighting strong market interest, and potential investors can buy fractional shares through brokerage accounts or explore options trading for shorting the stock.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ZCMD?" and start using high-conviction signals backed by rigorous historical data.

ZCMD

$0.2365+Infinity%1D

Analyst Views on ZCMD

About ZCMD

Zhongchao Inc is a holding company engaged in the provision of healthcare information, education, and training services to healthcare professionals and the public in China. The Company operates its businesses through two segments. MDMOOC Services segment engages in the provision of training and education services and assistance in patient-aid projects. Sales of Patented Drugs segment mainly engages in the sales of patented drugs. Under the MDMOOC brand, the Company offers a wide range of online and onsite health information services, healthcare education programs, and healthcare training products, consisting primarily of clinical practice training, open classes of medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content to healthcare professionals as well as the public.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Align Technology Reports Strong Q4 Earnings Beat

3 days agoBenzinga

Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.

FuelCell Energy Files for $200 Million Stock Offering, Shares Drop 8.9%

Dec 31 2025Benzinga

Stock Offering: FuelCell Energy announced an amended sales agreement to increase the total amount of shares available for sale to $200 million, which led to an 8.9% drop in share price to $7.23 on Wednesday, indicating a negative market reaction to the dilution of shares.
Market Reaction: The announcement of the stock offering raised investor concerns, as the significant drop in share price could impact the company's future fundraising capabilities and market confidence, particularly in the current economic climate where investors are sensitive to equity dilution.
Funding Purpose: FuelCell Energy plans to use the proceeds from this offering to support its R&D and operational expenditures, and while the stock faces short-term pressure, successful fundraising could provide the necessary capital to drive technological innovation and market expansion in the long run.
Industry Impact: In the context of increasing competition in the hydrogen and fuel cell industry, FuelCell Energy's stock offering may affect its reputation among investors, especially as the effectiveness of its financing strategy will directly influence its market position compared to other competitors.

OceanFirst Financial Corp. Announces $579 Million All-Stock Acquisition of Flushing, Shares Drop 7.4%

Dec 30 2025Benzinga

Acquisition Announcement: OceanFirst Financial Corp. has announced a $579 million all-stock acquisition of Flushing Financial, which aims to enhance market share, yet the stock price fell 7.4%, indicating a negative market reaction to the deal.
Market Reaction: Following the acquisition news, OceanFirst's shares dropped to $18.15, reflecting investor uncertainty regarding integration risks and potential returns, which may impact the company's short-term capital flow.
Strategic Implications: This acquisition represents OceanFirst's strategic move to expand its presence in the New Jersey market, potentially increasing its customer base and long-term profitability, although short-term stock volatility may undermine investor confidence.
Investor Focus: As the acquisition progresses, the market will closely monitor how OceanFirst manages the integration process and its impact on financial performance, especially in the current economic climate where investors are cautious about the banking sector.

ZCMD, ABCL, VOR, IXHL, OVID, BFRG Surge in After-Hours Trading Due to Clinical Progress and Recent Developments

Oct 02 2025NASDAQ.COM

Biotech Stocks Surge: Several biotech and healthcare stocks experienced significant after-hours gains on October 1, driven by technical momentum and recent clinical updates, despite the absence of new filings or press releases.
Zhongchao Inc. and AbCellera Biologics: Zhongchao Inc. saw a 14.04% increase after hours, while AbCellera Biologics rose 11.41%, both benefiting from prior trial data and analyst commentary rather than new announcements.
Vor Biopharma and Incannex Healthcare: Vor Biopharma rebounded 9.53% after a previous drop, and Incannex Healthcare gained 6.48%, with both companies relying on earlier clinical trial results to influence trading.
Ovid Therapeutics and Bullfrog AI Holdings: Ovid Therapeutics shares rose 8.03% following a positive earnings report, while Bullfrog AI Holdings advanced 3.44% after announcing an expansion of its sales and marketing team.

Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Jun 12 2025Benzinga

Oracle Corporation Financial Results: Oracle's shares rose 7.6% in pre-market trading after reporting fourth-quarter revenue of $15.9 billion and adjusted earnings of $1.70 per share, both exceeding analyst expectations.
Pre-Market Stock Movements: Several stocks experienced significant changes in pre-market trading, with Healthcare Triangle, Inc. surging 141.3% and Intensity Therapeutics, Inc. plummeting 47.7% following their respective announcements.